Fig. 5From: A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practiceSurvival curves of KRAS mutant NSCLC (A). The PFS survival curves between immunotherapy and chemotherapy group in KRAS mutant NSCLC patients (B). The PFS survival curves between treatment containing pemetrexed and containing paclitaxel in KRAS mutant NSCLC patients (C). The PFS survival curves between treatment with and without antiangiogenic therapy in KRAS mutant NSCLC patients (D). The OS survival curves between immunotherapy and chemotherapy group in KRAS mutant NSCLC patients (E). The OS survival curves between treatment containing pemetrexed and containing paclitaxel in KRAS mutant NSCLC patients (F). The OS survival curves between treatment with and without antiangiogenic therapy in KRAS mutant NSCLC patients (G). The PFS survival curves between immunotherapy and chemotherapy group in expression≥1% subgroup (H). The PFS survival curves between treatment with and without antiangiogenic therapy in non-G12C KRAS subgroup (I). The OS survival curves between treatment with and without antiangiogenic therapy in non-G12C KRAS subgroupBack to article page